Abstract Purpose: To compare the intestinal absorption of flumequine (FLM) and oxytetracycline (OTC) in
INTRODUCTION
Flumequine (FLM) from the quinolone family, and oxytretracycline (OTC) from the tetracycline family are two broad-spectrum antibiotics that are widely used in veterinary medicine [1] . Indeed, FLM was the first quinolone used in human and veterinary therapy [2] . It is currently used extensively in fish farming and aquaculture for the treatment of bacterial diseases such as enteric infections and gill diseases. Similarly, OTC is used in various curative treatments in animal breeding, especially in aquaculture and fish farming [1] . However, despite the good oral bioavailabilities of both antibiotics, their intestinal absorptions are altered by concomitant [3, 4] . This phenomenon reduces the amount of active ingredient (AI) available for absorption [4] . Thus, it can significantly reduce the antibacterial activities of the administered antibiotics [4] . This constitutes a major concern because in animal breeding, the preferred practice in the treatment of certain infections entails the incorporation of certain drugs in the diet. Indeed, many studies have focused on chelation phenomena that alter oral bioavailability in situations of simultaneous administration of antacids containing aluminum and quinolone [5] . This chelation has been observed also with OTC. The protection of antibiotics against divalent ions can increase their intestinal passage and thus, their antibacterial activities.
-----------------------------------------------------------------------------------------------------------------------------------------------------
Major research efforts are devoted to the development of new pharmaceutical formulations based on nanoparticles capable of protecting and controlling the release of AIs in the intestine. This is the case with the metal organic framework of iron III [MIL-100 (Fe) hybrid solid] [6] , which possesses the unique power of molecular inclusion. It offers protection to the AI of interest sensitive to possible interactions with certain constituents of the harmful gastrointestinal environment. It is in this perspective that MIL-100 (Fe) is used to protect aspirin against enzymatic degradation (for better gastrointestinal absorption), while protecting the patient from its irritating effects on the stomach [7] . The purpose of this work was to develop an oral formulation for protecting FML and OTC from divalent and trivalent ions in order to improve their bioavailability by encapsulating them in MIL-100 (Fe).
EXPERIMENTAL Materials
D-glucose, bumetanide hydrochloride, trimesic acid and ferric chloride hexahydrate were obtained from Sigma (St. Quentin-Fallavier, France). Oxytetracycline and flumequine were products of Sigma (St. Louis, USA). MIL-100(Fe) nanocapsules were gifted by F. Ben Ayed of Lavoisier Institute, Versailles-Paris [6] .
Permeation studies

Animals
Male mice (20 -25 g) were used in this study. They were provided by Janvier SAS (St Berthevin, France), and were given feed and clean water ad libitum, and housed singly in metabolism cages. The experimental protocols and animal handling conformed with the provisions of the Guide for the Care and Use of Laboratory Animals of the National Institute of Health, and the research ethics of Diderot University -Paris 7, conformed Directive 2010/63/EU of the European Parliament and of the council [8] .
Following an 18-h fast, the mice were subjected to sacrifice under carbon dioxide inhalation. Jejunum samples were excised, rinsed in isotonic Ringer's solution, and cut flat open through the mesenteric axis. The jejunum slices were then mounted in Ussing chambers in line with established procedure [9, 10] .
Determination of trans-epithelial electrical conductance
The Ringer's solution (pH 7.4) used comprised 25 mM NaHCO 3, 2.4 mM K 2 HPO 4, 115 mM NaCl, 1.2 mM MgCl 2 , 1.2 mM CaCl 2 , and 0.4 KH 2 PO 4 . The solution was aerated continuously in the Ussing chambers at 37 °C with air containing 5 % CO 2 . The spontaneous transmural electrical potential difference (PD) between the mucosa of serosa jejunum and the mucosa of the luminal jejuna was determined through 3 M KClcontaining 4 % agar bridges on the two sides of the jejunum linked to high-impedance voltmeter and calomel half-cells. Through short-circuiting current (I sc ), 0 mV PD was sustained for the duration of the study [11, 12] .
A continuous record of I sc , which is a measure of trans-epithelial ionic permeability, was produced with Biodaqsoft software. The I sc adjusted for fluid resistance, is the net trans-epithelial ion flux when electrochemical gradient is absent. Transepithelial electrical conductance (G t ) was estimated from Ohm's law as the inverse of resistance.
Measurement trans-epithelial flux of OTC and FLM
When a steady state was attained with respect to electrical parameters, pairs of jejunum tissues were matched based on their conductance values. Then, OTC and FLM were separately added to the mucosa chamber. At 60-min intervals, the other chamber was sampled in 1-mL aliquots which were replaced on withdrawal with an equivalent volume of Ringer's isotonic solution. A total of 4 samples were collected (0 -240 min) and subjected to UV measurements in a spectrophotometer at 327 (for FLM) and 374 nm (for OTC). The absorbance values were used for the determination of unidirectional fluxes (J ms ) [13] .
Statistical analysis
Data are presented as mean ± standard error of the mean (SEM), and analysed statistically with one-way analysis of variance (ANOVA) in combination with Dunnett's multiple comparison test. Values of p < 0.05 were taken as indicative of statistically significant differences.
RESULTS
Trans-epithelial flux of OTC and FLM
The intestinal flux of encapsulated OTC (OTCNPs) increased significantly, relative to the fluxes of non-encapsulated OTCs (control) (Jms = 0.072 ± 0.016 μg/h/cm 2 for OTC-NPs, versus 0.021 ± 0.05 μg/ h/cm 2 for OTC, p ˂ 0.05). In addition, the intestinal flux of encapsulated FLMs (FLM-NPs) increased significantly, compared to the flux of non-encapsulated FLMs (control) (Jms = 0.045 ± 0.006 μg/h/cm 2 for FLM-NPs, versus 0.004 ± 0.0008 μg/h/cm 2 for FLM, p ˂ 0.05).
Intestinal functional viability
The physical and functional viabilities of the tissues are usually monitored at the end of the study by measuring the transport of electrogenic ions due to the tissue response after stimulation. Forskolin (0.1 mM) was added to the serosal side of the tissue to induce electrogenic absorption [14] , followed by bumetanide (0.1 mM) on the same side, to induce inhibition of the generation of electrogenic ions. Variations in Isc indicate the physical and functional viabilities of the tissue at the end of the permeation studies [9] . The results are shown in Figure 1 . 
DISCUSSION
The usefulness of metal organic frameworks (MOFs) have been demonstrated in many applications, particularly in biomedicine due to their ability to encapsulate and release active molecules. Various studies have shown that MIL-100 (Fe), an MOF, is widely used to encapsulate active molecules. Indeed, the use of nanoparticle derivatives of active ingredients is a common strategy for enhancing their systemic absorptions.
Active ingredients can be encapsulated for intended release into the gastrointestinal medium or through the intestinal mucosa. Thus, flurbiprofen, a poorly-soluble antiinflammatory agent in aqueous solutions, has been encapsulated in nano MIL-100 (Fe), resulting in a relatively prolonged and promising release of the molecule [16] .
In the present study, the antibiotics FLM and OTC were protected from divalent ions that hinder their intestinal absorptions by the formation of non-absorbable chelates through their encapsulation in MIL-100 (Fe). Indeed, available literature has shown that simultaneous production of quinolones with Ca 2+ , Mg 2+ , Al 3+ leads to the formation of complexes [17] that reduce their intestinal absorptions, and thus their antibacterial activities [15] . This phenomenon of chelation by metal ions is also observed with tetracycline [3, 4] . The antibiotics FLM and OTC are widely used in animal farming, especially in fish farming, in which the ionic composition of the marine environment is rich in divalent ions such as Ca 2+ and Mg 2+ . However, for better treatment in the case of mass rearing, these antibiotics are mixed with fish feed. Hence, it is preferable to protect the antibiotics so as to ensure their optimum antimicrobial effects through their safe delivery.
In the present study, the permeations of encapsulated FLM and OTC in the Ussing chamber in the presence of Ringer's solution increased their intestinal passages 10 folds and 5 folds, respectively, when compared with controls.
These increases in permeation were probably due to the cage protection of MIL-100 (Fe) from the divalent ions which allowed the safe deliveries of the antibiotics. Moreover, iron may interact with the narrow junctions of intestinal epithelial cells, and thus increase the permeability of the intestinal wall [18] . This mechanism may explain the significant increases in the fluxes of the encapsulated antibiotics through the intestinal wall, relative to the free antibiotics.
CONCLUSION
The findings of this study indicate that encapsulation of active ingredients by MIL-100 (Fe) nanoparticles shows a strong potential for improving the oral bioavailability of these active molecules. Thus, nanoparticle encapsulation can be considered a good platform for formulations aimed at protecting antibiotics such as flumequine and oxytetracycline which are susceptible to chelation by divalent and trivalent ions.
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